Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Fluocinonide Cream
Generic Name
Fluocinonide
Active Ingredient
FluocinonideCategory
Corticosteroid [EPC]
Variants
2
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| .5 mg/g | CREAM | TOPICAL | 69238-1534 |
| .5 mg/g | CREAM | TOPICAL | 68788-8105 |
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Fluocinonide Cream, you must consult a qualified healthcare professional.
Detailed information about Fluocinonide Cream
Fluocinonide is a high-potency topical corticosteroid used to reduce inflammation and itching associated with various skin conditions like psoriasis and eczema. It works by suppressing the immune response and constricting blood vessels in the affected area.
For most inflammatory skin conditions, the standard adult dosage for fluocinonide (0.05%) is to apply a thin film to the affected area two to four times daily, depending on the severity of the condition and the healthcare provider's recommendation. For the high-potency 0.1% cream (Vanos), the typical application is once or twice daily.
Healthcare providers generally advise using the smallest amount necessary to cover the affected area. Treatment should be limited to the shortest duration possible to achieve the desired clinical response. If no improvement is seen within two weeks, patients should contact their doctor for a re-evaluation of the diagnosis.
Fluocinonide is a high-potency steroid and must be used with extreme caution in pediatric patients. Children have a larger skin surface area relative to their body weight, which increases the risk of systemic absorption and side effects like HPA (hypothalamic-pituitary-adrenal) axis suppression.
Because fluocinonide is applied topically and systemic absorption is generally low, specific dosage adjustments for patients with kidney disease are usually not required. However, if large areas are being treated or if the skin barrier is severely compromised, monitoring for systemic effects may be necessary.
Since systemic fluocinonide is metabolized by the liver, patients with severe hepatic (liver) failure should be monitored closely if the medication is used over large surface areas, as their ability to clear absorbed steroid may be reduced.
Clinical studies have not identified significant differences in safety between elderly and younger patients. However, because older adults often have thinner, more fragile skin, they may be at a higher risk for skin atrophy (thinning) and increased systemic absorption. Healthcare providers typically recommend the lowest effective dose for the shortest duration.
If you miss a dose, apply it as soon as you remember. However, if it is almost time for your next scheduled application, skip the missed dose and return to your regular routine. Do not apply extra medication to 'make up' for a missed dose, as this increases the risk of local skin irritation.
Acute overdose from topical application is rare. However, chronic overuse (using too much for too long) can lead to systemic absorption. Symptoms of chronic overdose (Cushing's syndrome) include a 'moon face,' weight gain in the upper back and torso, and high blood pressure. If you suspect someone has swallowed the medication, contact a poison control center or seek emergency medical help immediately.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or stop using the medication abruptly without medical guidance, as some conditions may 'rebound' if the steroid is stopped too quickly.
Most patients tolerate fluocinonide well when used as directed. However, local skin reactions at the site of application are common. These may include:
These symptoms are usually mild and often resolve as the skin adjusts to the medication. If they persist or worsen, consult your healthcare provider.
Fluocinonide is a potent medical treatment and should never be shared with others or used for skin conditions for which it was not prescribed (such as diaper rash or acne). It is for external use only. Avoid contact with the eyes, as this can lead to serious ocular complications. If the medication accidentally gets into your eyes, rinse thoroughly with cool water for several minutes.
There are no FDA black box warnings for Fluocinonide. However, its potency necessitates careful adherence to prescribed limits on duration and surface area coverage.
There are no specific drugs that are absolutely contraindicated with topical fluocinonide because systemic levels are usually very low. However, you should never use fluocinonide alongside other high-potency topical steroids (like clobetasol) unless specifically directed, as this dramatically increases the risk of skin atrophy and HPA axis suppression.
Fluocinonide must NEVER be used in the following circumstances:
Fluocinonide is classified as FDA Pregnancy Category C. This means that animal studies have shown an adverse effect on the fetus (such as cleft palate when administered systemically at high doses), but there are no adequate, well-controlled studies in pregnant women.
During pregnancy, fluocinonide should be used only if the potential benefit justifies the potential risk to the fetus. If used, it should not be applied in large amounts or for long periods. Healthcare providers typically avoid prescribing high-potency steroids during the first trimester unless absolutely necessary.
It is not known whether topical application of fluocinonide results in sufficient systemic absorption to produce detectable amounts in breast milk. However, systemic corticosteroids are secreted into breast milk. To minimize risk, breastfeeding women should not apply fluocinonide to the breast or nipple area to prevent the infant from accidentally ingesting the drug. If the medication is needed on other parts of the body, use the smallest amount possible.
Pediatric patients are at a higher risk for systemic toxicity from topical steroids. There have been reported cases of HPA axis suppression, Cushing's syndrome, and intracranial hypertension (increased pressure in the brain) in children using topical corticosteroids. Chronic use can also interfere with growth and development. Use in children must be limited to the shortest duration possible and monitored closely by a pediatrician.
Fluocinonide is a fluorinated corticosteroid. The addition of fluorine atoms to the steroid nucleus increases its potency and resistance to metabolic breakdown in the skin. Its primary mechanism involves binding to the cytoplasmic glucocorticoid receptor. This complex then translocates to the nucleus, where it modulates gene expression. Specifically, it inhibits the transcription of pro-inflammatory genes (like those for COX-2 and various cytokines) and increases the expression of anti-inflammatory genes (like Lipocortin-1). This results in reduced capillary permeability, decreased migration of white blood cells to the area, and a reduction in the release of inflammatory mediators.
The potency of fluocinonide is often measured using the Stoughton-McKenzie vasoconstrictor assay. This test measures the degree of skin blanching (whitening) caused by the medication, which correlates with its anti-inflammatory strength. Fluocinonide is categorized as a High Potency (Group II) steroid, making it significantly stronger than hydrocortisone (Group VII) but slightly less potent than clobetasol propionate (Group I).
| Parameter | Value |
Common questions about Fluocinonide Cream
Fluocinonide is a high-potency prescription corticosteroid used to treat a variety of inflammatory skin conditions, including psoriasis, atopic dermatitis (eczema), and seborrheic dermatitis. It works by reducing the swelling, redness, and intense itching associated with these disorders by suppressing the local immune response. Because it is a potent Group II steroid, it is typically reserved for moderate-to-severe cases that have not responded to milder over-the-counter treatments. Healthcare providers may prescribe it in various forms, such as creams, ointments, or gels, depending on the location and nature of the skin lesion. It is important to use it only for the specific condition diagnosed by your doctor, as it is not suitable for all types of skin rashes.
The most common side effects of fluocinonide occur at the site of application and include temporary burning, stinging, itching, or skin dryness. Some patients may also notice small red bumps or whiteheads, a condition known as folliculitis, or a temporary lightening of the skin color (hypopigmentation). These local reactions are usually mild and often subside as the skin becomes accustomed to the medication. However, if these symptoms are severe or if you notice skin thinning, stretch marks, or spider veins, you should contact your healthcare provider immediately. Long-term use or application to large areas can also lead to more serious systemic side effects, though this is less common with proper use.
There is no known direct chemical interaction between topical fluocinonide and alcohol consumption. However, alcohol is a vasodilator, meaning it can cause blood vessels to widen, which may lead to increased skin flushing and potentially worsen the redness and itching of conditions like psoriasis or rosacea. Furthermore, heavy alcohol use can weaken the immune system and impair the skin's ability to heal. While a moderate amount of alcohol is unlikely to interfere with the medication's effectiveness, it is always best to discuss your lifestyle habits with your doctor to ensure the best possible outcome for your skin condition. Avoiding alcohol may help reduce 'flares' in certain inflammatory dermatoses.
Fluocinonide is classified as a Category C medication, meaning that its safety during pregnancy has not been fully established in human studies. Animal studies have shown that high doses of corticosteroids can cause birth defects, although the risk from topical application to small areas of the skin is generally considered low. Healthcare providers typically recommend using fluocinonide during pregnancy only if the potential benefits outweigh the risks to the developing fetus. If it is prescribed, it should be used at the lowest possible dose for the shortest duration. Pregnant women should avoid applying the medication to large surface areas or using it with bandages that cover the skin, as this increases the amount of drug that enters the bloodstream.
Most patients begin to notice a reduction in itching and redness within the first few days of using fluocinonide. For chronic conditions like plaque psoriasis, it may take one to two weeks of consistent use to see a significant improvement in the thickness and scaling of the skin. If you do not see any improvement after two weeks of regular application, you should contact your healthcare provider, as they may need to re-evaluate your diagnosis or adjust your treatment plan. It is important not to use the medication for longer than prescribed, even if it is working well, to avoid the risk of skin thinning or other long-term side effects.
If you have been using fluocinonide for a short period (less than two weeks), you can usually stop using it without any issues once your skin has cleared. However, if you have been using it for an extended period or on a large area of the body, stopping suddenly can cause a 'rebound effect,' where your skin condition returns and may be even worse than before. In some cases, abrupt discontinuation can lead to topical steroid withdrawal, characterized by intense redness, burning, and skin sensitivity. To prevent this, your doctor will likely advise you to gradually taper off the medication by applying it less frequently over the course of a week or two.
If you miss a scheduled application of fluocinonide, you should apply it as soon as you remember. However, if it is nearly time for your next scheduled dose, skip the missed application and continue with your regular routine. You should never apply a double amount of the medication to make up for a missed dose, as this does not improve efficacy and only increases the risk of local skin irritation and systemic absorption. Consistency is key to managing inflammatory skin conditions, so try to apply the medication at the same times each day to maintain a steady therapeutic effect on the skin.
When used correctly as a topical treatment, fluocinonide is very unlikely to cause weight gain. Weight gain is a classic side effect of systemic corticosteroids (like oral prednisone) or the over-absorption of topical steroids leading to Cushing's syndrome. Cushing's syndrome occurs only when large amounts of the steroid enter the bloodstream over a long period, causing fat redistribution to the face and torso. If you notice rapid weight gain, a rounded face, or a fatty hump between your shoulders while using fluocinonide, you should contact your doctor immediately, as these are signs that too much of the medication is being absorbed into your system.
Fluocinonide can generally be used alongside most oral medications, but you should always inform your doctor about all the drugs you are taking. Interactions are rare because the medication is applied to the skin, but using it with other topical steroids or certain systemic drugs like ritonavir (an HIV medication) can increase the risk of side effects. You should also be cautious when using other skin products, such as medicated cleansers or cosmetics, on the treated area, as these can increase irritation or change how the fluocinonide is absorbed. Always wait at least 30 minutes after applying fluocinonide before applying any other creams or moisturizers to the same area.
Yes, fluocinonide is widely available as a generic medication in several forms, including 0.05% cream, ointment, gel, and solution. Generic versions are required by the FDA to have the same active ingredient, strength, and effectiveness as the brand-name versions (such as Lidex, which is now discontinued). The 0.1% high-potency cream is also available as a generic for the brand Vanos. Choosing the generic version can significantly reduce the cost of treatment for most patients. However, the 'vehicle' or inactive ingredients (like preservatives and thickeners) may vary slightly between manufacturers, so if you have sensitive skin, you should check the label for potential allergens.
Other drugs with the same active ingredient (Fluocinonide)
While rare with topical use, systemic absorption can lead to serious complications.
> Warning: Stop taking Fluocinonide and call your doctor immediately if you experience any of these:
Prolonged use of fluocinonide (typically longer than 2–4 weeks) increases the risk of permanent skin changes. Skin thinning (atrophy) can make the skin more prone to bruising and tearing. There is also the risk of 'topical steroid withdrawal' or 'red burning skin syndrome,' where the skin becomes intensely red, burning, and itchy after the medication is stopped. To prevent this, healthcare providers often recommend a 'tapering' schedule where the frequency of application is slowly reduced.
No FDA black box warnings are currently issued for fluocinonide. However, the FDA requires all high-potency topical corticosteroids to carry warnings regarding the risk of HPA axis suppression, Cushing's syndrome, and growth retardation in children.
Report any unusual symptoms to your healthcare provider. Early detection of side effects can prevent permanent skin damage or systemic complications.
Patients using large doses of fluocinonide or applying it to large surface areas may require periodic monitoring for HPA axis suppression. Common tests include:
Fluocinonide is not known to affect the ability to drive or operate machinery. However, if you experience systemic side effects like dizziness or vision changes, avoid these activities and consult your doctor.
There are no known direct interactions between alcohol and topical fluocinonide. However, alcohol can cause vasodilation (widening of blood vessels), which may worsen the redness and itching of certain skin conditions like psoriasis or seborrheic dermatitis.
Do not stop using fluocinonide suddenly if you have been using it for a long period. Abrupt discontinuation can lead to a 'rebound flare' of your skin condition. Your healthcare provider will likely instruct you to gradually reduce the frequency of application (e.g., from twice daily to once daily, then every other day) before stopping completely.
> Important: Discuss all your medical conditions with your healthcare provider before starting Fluocinonide, especially if you have a history of poor circulation, diabetes, or immune system problems.
There are no known interactions between fluocinonide and specific foods. Unlike oral steroids, topical fluocinonide absorption is not affected by diet. However, maintaining a healthy, anti-inflammatory diet may support the overall management of conditions like psoriasis.
Fluocinonide may interfere with certain diagnostic tests:
For each major interaction, the management strategy is usually to use the lowest effective dose for the shortest time and to monitor for signs of systemic absorption.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter creams or ointments.
Conditions requiring careful risk-benefit analysis by a doctor include:
Patients who have had an allergic reaction to other corticosteroids (such as triamcinolone, betamethasone, or hydrocortisone) may also be allergic to fluocinonide. This is known as cross-sensitivity. If you have a history of 'steroid allergy,' your doctor may perform a patch test before prescribing fluocinonide.
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Fluocinonide. Always disclose any history of skin infections or previous reactions to skin creams.
Older patients may be more sensitive to the effects of fluocinonide due to age-related skin thinning. They are also more likely to have comorbid conditions like diabetes or glaucoma that could be worsened if the steroid is absorbed systemically. Dose selection should be cautious, usually starting at the lower end of the dosing range.
No specific dose adjustments are provided in the manufacturer's labeling for patients with renal impairment. However, since the kidneys excrete absorbed metabolites, patients with end-stage renal disease should be monitored for systemic steroid effects if large areas are treated.
Patients with significant liver disease (Child-Pugh Class B or C) may have a reduced ability to metabolize fluocinonide that enters the systemic circulation. While topical use is generally safe, these patients should avoid long-term use over large surface areas to prevent accumulation of the drug in the body.
> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant, planning to become pregnant, or nursing.
| Bioavailability | Variable (Topical: <5% on intact skin; higher with occlusion) |
| Protein Binding | ~90% (primarily albumin) |
| Half-life | Systemic half-life is approximately 1.5 to 3.5 hours |
| Tmax | Not applicable for topical (local effect is immediate) |
| Metabolism | Hepatic (liver) via oxidation and conjugation |
| Excretion | Renal (~70%), Fecal (~30%) |
Fluocinonide is classified as a Corticosteroid, Potent (Group II). It is related to other topical steroids like betamethasone dipropionate and triamcinolone acetonide but is specifically modified for high lipid solubility to enhance skin penetration.